ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Clinical Trials Approved By NCI During November Are Listed

December 27, 2002

Revive Comprehensive Program, But Don’t Tie It to Grant Review, Center Executive Agrees

July 29, 1988

Bayh To Receive ACCC Annual Award

February 8, 1980

Better Access Key To Higher Survival For African-Americans With Colon Cancer

August 30, 2002

“NIH Reveres, Honors, respects And Defends One And Only One Mechanisms’ – R01s

September 20, 1991

Enter The Cancer Letter’s 35th Anniversary Story Contest

July 31, 2009